Details

Autor(en) / Beteiligte

• Falzone, E
• Auroy, Y
• Hoffmann, C
• Sandid, I
• Carlier, M
• Benhamou, D
• Andreu, G
• Lienhart, A

Titel

Errors of red cell concentrates recipients: method of analysis using the adverse events notified to the hemovigilance network in 2009

Ist Teil von

• Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2012-12, Vol.19 (6), p.338

Ort / Verlag

France

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• Among the adverse events in the blood transfusion process, transfusion to a "wrong" patient is potentially dangerous, as it can lead to an adverse reaction at least in case of ABO incompatible red cell concentrate. The "Root Cause Analysis" working party of the National Hemovigilance Commission developed a tool to collect this type of adverse event, and tested it on a sample of 43 cases involving red cell concentrates notified between March, 2009 and February, 2010. One hundred and nine failures of a step in the transfusion process were observed, i.e. 2.5 failures per adverse event. Failures may occur early in the process. However, they are mainly found at the time of issuing of the blood component, and further, in the clinical ward. How the failure is eventually detected is not always described when the blood component has been fully transfused, in contrast with the cases where actual transfusion to the wrong patient has been prevented. Knowing the way of failure detection enables an objective approach of the efficacy of the numerous existing safety measures. In this sample, bedside controls (documents check as well as the use of anti-A and anti-B reagents with patient's blood and red cell concentrates) detected the failure in three cases out of 34, which were not detected before, showing an efficacy similar to the administrative control done at reception in the clinical ward. The document, set up to analyse step by step these cases of patient errors, will be used in the future to analyse all similar cases, not only with red cell concentrates, but also with platelet concentrates and fresh frozen plasma, ultimately in order to improve their prevention.